Cargando…

Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies

BACKGROUND: Most patients with chronic plaque psoriasis receive topical treatment; however, available options lack a balance of efficacy with long-term safety and tolerability. Roflumilast cream 0.3% is a highly potent phosphodiesterase 4 (PDE4) inhibitor approved by the US FDA for treatment of psor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thurston, Archie W., Osborne, David W., Snyder, Scott, Higham, Robert C., Burnett, Patrick, Berk, David R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968262/ https://www.ncbi.nlm.nih.gov/pubmed/36422852 http://dx.doi.org/10.1007/s40257-022-00741-9

Ejemplares similares

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
por: Stein Gold, Linda, et al.
Publicado: (2022)

A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis
por: Cai, Lin, et al.
Publicado: (2020)

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials
por: Suleiman, Ahmed A., et al.
Publicado: (2019)

Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics
por: Jett, John E., et al.
Publicado: (2021)

Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study
por: Liu, Lunfei, et al.
Publicado: (2019)

Management of Plaque Psoriasis in Adults: Clinical Utility of Tapinarof Cream
por: Spencer, Riley K, et al.
Publicado: (2023)

Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials
por: Desai, Seemal R., et al.
Publicado: (2023)

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial
por: Zirwas, Matthew J., et al.
Publicado: (2023)

Safety and Efficacy of a Novel Combination Cream (GN-037) in Healthy Volunteers and Patients with Plaque Psoriasis: A Phase 1 Trial
por: Sezer, Zafer, et al.
Publicado: (2023)

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
por: Gong, Xiaohua, et al.
Publicado: (2021)

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies
por: Körber, Andreas, et al.
Publicado: (2018)

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
por: Torres, Tiago, et al.
Publicado: (2023)

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
por: Yosipovitch, Gil, et al.
Publicado: (2018)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Subcutaneous Injection of Allogeneic Adipose-Derived Mesenchymal Stromal Cells in Psoriasis Plaques: Clinical Trial Phase I
por: Bajouri, Amir, et al.
Publicado: (2023)

The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
por: Papp, Kim A., et al.
Publicado: (2021)

The CREAM-III Calorimeter
por: Malinin, A, et al.
Publicado: (2007)

Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results
por: Hong, Jin-Bon, et al.
Publicado: (2022)

Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)
por: Gyldenløve, Mette, et al.
Publicado: (2023)

A phase I and pharmacokinetic study of amphethinile.
por: Smith, D. B., et al.
Publicado: (1988)

Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Nakamura, Mio, et al.
Publicado: (2017)

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
por: Cai, Lin, et al.
Publicado: (2021)

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
por: Papp, K.A., et al.
Publicado: (2017)

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
por: Armstrong, April W., et al.
Publicado: (2018)

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Paller, A.S., et al.
Publicado: (2020)

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
por: Suleiman, Ahmed A., et al.
Publicado: (2018)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study
por: Oliver, R., et al.
Publicado: (2021)

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
por: Kimball, A.B., et al.
Publicado: (2019)

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
por: Van Voorhees, A.S., et al.
Publicado: (2021)

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study
por: Seo, Seong Jun, et al.
Publicado: (2020)

A population pharmacokinetic and pharmacokinetic‐pharmacodynamic analysis of vupanorsen from phase I and phase II studies
por: Ahn, Jae Eun, et al.
Publicado: (2023)

Phase I Study to Assess Safety of Laser-Assisted Topical Administration of an Anti-TNF Biologic in Patients With Chronic Plaque-Type Psoriasis
por: Bauer, Martin, et al.
Publicado: (2021)

Purpuric and cream-colored plaques in an immunocompromised person: A case of disseminated trichosporonosis
por: Wan, Joy, et al.
Publicado: (2016)

Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab
por: Morcos, Peter N., et al.
Publicado: (2023)

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
por: Gordon, Kenneth B., et al.
Publicado: (2022)

Non‐invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator‐initiated, phase IV, unicentric, open, randomized clinical trial
por: Yélamos, O., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n28fiskv5nid6pa1o0ekdvob3p